BioInvent's CEO highlights TNFR2 data recently presented at ESMO, and more in the company's pipeline

blonca9
Sep 19, 2024
1 min read

Martin Welschof describes this target that BioInvent is at the forefront of, including single agent data they have seen, and covers other programs in the company's pipeline.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

BioInvent's CEO highlights TNFR2 data recently presented at ESMO, and more in the company's pipeline

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight